You just read:

Race Oncology Signs Exclusive License Agreement with BL&H Korea for the Sale of Bisantrene, an Agent for Treating Acute Myelogenous Leukemia, in South Korea

News provided by

Race Oncology

03 Apr, 2017, 00:01 BST